

Minireview Article

Open Access



Clinically Important *Yersinia*: Minireview

Zaid Sahib Dheyab

Corresponding Author: Zaid Sahib Dheyab

Biology Department, college of science, university of Babylon, Iraq.



Abstract

Yersinia spp. is an enterobacteria that causes a prominent zoonotic diseases. Plague, Yersinosis, Far-East Scarlett-Like Fever and Kawasaki Disease were a common recorded diseases. While *Yersinia* genus compile 18 species, only three were clinically important human pathogens: *Y. pseudotuberculosis*, *Y. pestis* and *Y. enterocolitica*. Serotyping is common among *Yersinia* and used to distinguish between pathogenic and non-pathogenic species. Clinical symptoms ranged from high fever (up to 39 to 40°C), malaise, chills, and headache in Plaque to gastrointestinal symptoms usually resolve within 2 to 3 weeks. The complications may include, erythema nodosum, arthritis, Reiter's disease and glomerulonephritis, can occur. *Y. enterocolitica* and *Y. pseudotuberculosis* may associate with mesenteric lymphadenitis, terminal ileitis, pseudo-appendicitis and sepsis. Manipulation of *Yersinia* may require biosafety level 3 laboratory and all immunological, and molecular assay targeting F1 antigen for diagnosis. *Yersinia* have arrays of virulence factors includes: Ypm (responsible for superantigen symptoms), pYV(plasimd who carry set of virulence genes: Yops, outer membrane proteins; YadA, an adhesin who binds to collagen and laminin and eliciting inflammatory responses), HPI (The high-pathogenicity island which carry: Psn, an receptor for the siderophore; irp1 and irp2 which encode high-molecular-weight proteins involved in synthesis of yersiniabactin) and *Yersinia* Chromosomal Virulence Factors (YCVF):(i) invA, encoding an invasin, (ii) ail, encoding a protein that mediates adhesion and invasion into host cells, and (iii) ystA or ystB, encoding enterotoxins that cause fluid accumulation in the intestines. The drug of choice are Streptomycin and gentamicin while many MDR isolates were reported worldwide and there is a relation between resistance style and serotypes of *Yersinia*. The current review conclude importance of *Yersinia* spp. as a zoonotic pathogen equipped with group of virulence traits and resistance to antibiotics that may push a real threat for infected person.

Keywords: *Yersinia* spp., Plaque, Yersinosis, Kawasaki Disease, pYV, YPM

Copyright : © 2021 The Authors. Published by Medical Editor and Educational Research Publishers Ltd. This is an open access article under the CC BY-NC-ND license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The genus *Yersinia* is gram-negative and belongs to the family of Enterobacteriaceae. The genus *Yersinia* includes 18 species (*Y. aldovae*, *Y. aleksiciae*, *Y. bercovieri*, *Y. enterocolitica*, *Y. entomophaga*, *Y. frederiksenii*, *Y. intermedia*, *Y. kristensenii*, *Y. massiliensis*, *Y. mollaretii*, *Y. nurmii*, *Y. pekkanenii*, *Y. pseudotuberculosis*, *Y. pestis*, *Y. rohdei*, *Y. ruckeri*, *Y. similis*, and *Y. wautersii*), of which *Y. pseudotuberculosis*, *Y. pestis* and *Y. enterocolitica* are pathogenic, but as *Y. pestis* is effectively a clone of *Y. pseudotuberculosis*, there are currently only two full species that are of clinical significance. The other species are commonly found in soil and water, and generally not pathogenic [1-5]. *Yersinia* are facultatively anaerobic, oxidase negative, and catalase-positive, and they do not form spores. The optimum growth temperature of *Yersinia* is 28-29°C and their growth range is 4-42°C, but *Y. enterocolitica* and *Y. pseudotuberculosis* can grow at temperatures near 0°C [6,7].

It is interesting that *Y. pseudotuberculosis* and *Y. enterocolitica* are among the most divergent of the species, and are now thought to have gained pathogenicity independently, although they cause similar gastrointestinal diseases in humans and also in animals. They also share pathogenicity islands and other virulence factors, now proposed to have been gained independently, presumably initially from other genera, but perhaps reaching the second species by transfer within the genus [8]. *Y. pseudotuberculosis* and *Y. enterocolitica* are enteropathogenic, while *Y. pestis* is the causative agent of plague. *Y. pseudotuberculosis* and *Y. pestis* are genetically highly similar and *Y. pestis* probably emerged from *Y. pseudotuberculosis* [9]. As genome sequences became available, many isolates first typed as *Y. pseudotuberculosis* were reclassified into other species that are now included in a group known as the 'Y. pseudotuberculosis complex'. The species include *Y. pseudotuberculosis* / *Y. pestis*, *Y. similis* [10,11]. *Y. enterocolitica* is well known as a cause of yersiniosis in children. This microorganism is ubiquitous in nature and has been isolated from different types of foods, animals, and environments [12]. Although,

numerous *Y. enterocolitica* biotypes have been isolated from nature, only a few are human pathogens [13]. The current review study intended to highlight the diseases, virulence factors and antibiotic resistance of *Yersinia* spp.

Yersinia pestis

Yersinia pestis, etiologic agent of plague, is one of the most successful zoonotic pathogens known. Molecular investigations have revealed that *Y. pestis* spread multiple times from its original foci in Central Asia to cause three recognized pandemics: Justinian's plague in the 6th–7th centuries, medieval plague in the 14th–17th centuries (including the Black Death), and the third pandemic, which began ~1855 in the Chinese province of Yunnan. *Y. pestis* remains a human health threat due to the severity of the disease, the many established natural plague foci, and its potential for use as a bioterror agent [14,15]. Fleas transmit *Y. pestis* from infected domestic rats to humans causing bubonic plague. *Y. pestis* also can be transmitted via respiratory secretions following contact with another infected human, leading to pneumonic plague. Currently, plague is still a public health threat in certain regions of Asia, Africa, North and South America. Because plague is highly contagious, *Y. pestis* can be used in biological warfare and is considered a Category A agent of bioterrorism [16].

Yersinia pestis isolates carry genes for the O:1b serotype, suggesting that it emerged from a *Y. pseudotuberculosis* O:1b progenitor [17]. However, in *Y. pestis*, four O-antigen genes have inactivating mutations, and an O antigen is not produced. Interestingly, genes specific to many of the *Y. pseudotuberculosis* O-antigen serotypes were identified in other species in the *Y. pseudotuberculosis* complex, which led to the proposal that the O-antigen serotyping scheme should apply to all members of this complex [18].

Yersinia pseudotuberculosis

It was first isolated in 1883 from tuberculosis-like lesions in guinea pigs. *Yersinia pseudotuberculosis* is a fecal-oral pathogen adept at contaminating chilled food stores due to the organisms ability to proliferate at temperatures as low as 4°C. *Y. pseudotuberculosis* is generally considered an enteric pathogen, but it has also

Clinically Important Yersinia: Minireview

been associated with other medical complications such as arthritis, erythema nodosum, desquamation, rash, pneumonia and nephritis. Yersiniosis caused by *Y. pseudotuberculosis* is often acquired through the ingestion of contaminated food, but zoonotic transmission is possible, and outbreaks have been reported in Finland, Russia and Japan [19,20]. Serotyping is a common *Y. pseudotuberculosis* typing method, dividing *Y. pseudotuberculosis* into 15 O-serotypes (O:1–O:15) and 10 subtypes (O:1a–O:1c, O:2a–O:2c, O:4a–O:4b, and O:5a–O:5b) based on variability in lipopolysaccharide O-antigen profiles. Most European *Y. pseudotuberculosis* isolates are of serotypes O:1–O:3, whereas serotypes O:4–O:15 are primarily found in Asia. All *Y. pseudotuberculosis* strains are considered potentially pathogenic, but only *Y. pseudotuberculosis* serotypes O:1–O:6 and O:15 have been clinically isolated. The most common clinical serotypes are O:1a, O:1b, and O:3 in Europe and O:4b and O:5b in the Far East. Serotypes O:7–O:14 have only been isolated from environmental and animal sources in Asia. *Y. pseudotuberculosis* can be assigned into 6 genetic groups (G1–G6) based on the presence of 3 key virulence factors: the *Y. pseudotuberculosis* virulence plasmid (pYV), the high pathogenicity island (HPI), and the subtype of *Y. pseudotuberculosis*-derived mitogen produced (YPMa/YPMb/YPMc). Interestingly, expression of the O-antigen component of the *Y. pseudotuberculosis* LPS is downregulated at 37°C, and this is also true for other *Yersinia* species. However, the O antigen is required for virulence, as well as for protection against antimicrobial chemokines such as polymyxin B. Thus, downregulation may be delayed until the later stages of infection [21,22].

Yersinia enterocolitica

Yersinia enterocolitica includes nonpathogenic biotype 1A and pathogenic biotypes 1B, 2, 3, 4, and 5 [23]. Pigs are the main reservoirs and vehicles for *Y. enterocolitica* transmission, but virulent strains have been also detected in milk and dairy products. Classification of *Y. enterocolitica* strains into biotypes or serotypes (or bioserotypes) is based on biochemical tests and the somatic O antigen (lipopolysaccharide or LPS), with six biotypes (1A, 1B, 2, 3, 4, and 5) and more than 57 serotypes. Nonetheless, most of

the strains belong to biotypes 2, 3, and 4 and to serotypes O:3, O:5,27, O:8, and O:9. *Y. enterocolitica* is subdivided into the *Y. enterocolitica* subspecies *enterocolitica*, which includes mainly biotype 1B, and the *Y. enterocolitica* subspecies *palaearctica*, which includes the remaining biotypes [24].

Clinical Symptoms of Yersinial Infections:

The first symptoms of plague are similar to those of the flu, with high fever (up to 39 to 40°C), malaise, chills, and headache. An important clue for suspecting plague is contact history with wild animals in natural plague foci or with other plague patients. If a patient develops sudden high fever after close contact with dead animals (rodents or other wild animals) in a region where plague is endemic, bubonic plague (with regional lymph node swelling), pneumonic plague (with severe coughing and pneumonic signs by X ray), or septicemic plague (with sudden high fever and chills) should be highly suspected. The incubation period is generally 2 to 3 days but may be as long as 6 days. If the patient is infected by inhaling a large quantity of *Y. pestis*, causing primary pneumonic plague, the incubation period might be 1 day or less, and the symptoms and signs may progress very quickly. In cases of bubonic plague, patients usually develop regional red, dry, and hot skin, with progressive severe pain in the flea-biting region and forced position caused by severe pain of the swollen lymph nodes [25,26].

Yersiniosis, which is caused by the enteric bacterial pathogens *Yersinia enterocolitica* and *Yersinia pseudotuberculosis*, was the third most commonly reported zoonotic infection in Europe in 2015 [27]. Transmission from animals to humans can occur via direct contact with animals or their environment, although most human gastrointestinal infections are foodborne. Outbreaks of yersiniosis associated with the consumption of contaminated meat and dairy products, and more recently salad vegetables, have been documented in the literature. Gastrointestinal symptoms usually resolve within 2 to 3 weeks without recourse to antibiotics, but secondary immunological complications, including erythema nodosum, arthritis, Reiter's disease and glomerulonephritis, can occur. Furthermore, *Y. enterocolitica* and *Y. pseudotuberculosis* are also associated with

Clinically Important Yersinia: Minireview

causing a number of other primary acute infections, including mesenteric lymphadenitis, terminal ileitis, pseudo-appendicitis and sepsis. Infection with *Y. pseudotuberculosis* causes acute abdominal pain and diarrhea. In immunocompromised persons or persons with underlying diseases, systemic infections are possible [28]. Diseases caused by superantigenic toxin-producing bacteria share clinical features such as the following: high-grade fever, conjunctival inflammation, pharyngeal inflammation, and latent development of an erythematous skin rash followed by desquamation in the convalescent phase. Superantigens have been shown to enhance susceptibility to lipopolysaccharide-induced shock [29,30].

Laboratory Diagnosis:

The gold standard for plague diagnosis in the laboratory is the isolation and identification of the plague pathogen from clinical specimens. The pathogen can be cultivated on many routinely used media, including brain heart infusion broth, MacConkey agar, and sheep blood agar. *Y. pestis* grows optimally at 26 to 28°C; however, incubation at 37°C is necessary for F1 antigen production. The colonies formed on the agar plate after a 48-h incubation are small (about 1 to 2 mm in diameter), with raised centers and a flat periphery. *Y. pestis* appears as small pleomorphic rods by Gram staining and bipolar coccobacilli by Giemsa or Wayson staining. The cultures could be specifically lysed by *Y. pestis* phage at 22 to 25°C. *Y. pestis* is not active in terms of biochemical assays; therefore, conventional biochemical identification systems sometimes result in misidentification with *Y. pseudotuberculosis* or other enterobacteria. Isolation of *Y. pestis* should be performed at minimum in a biosafety level 3 laboratory [31].

F1 antigen is typically used as a target to detect *Y. pestis* by immunological methods. A passive hemagglutination test and F1 antigen hemagglutination inhibition test are conventionally employed for detecting F1 antigen. However, direct fluorescent antibody testing and enzyme-linked immunosorbent assays have also been reported for detecting F1 antibody or F1 antigen quantitatively. *Y. pestis* can be detected by PCR targeting the F1 antigen gene (*caf1*), *pla* gene, or chromosomal fragments (such as fragment 3a). However, the *pla* gene and

chromosomal fragment targets were recently shown to be unreliable for detecting *Y. pestis*. Immunological and nucleic acid-based detection of *Y. pestis* can be performed in a biosafety level 2 laboratory. For areas without a supporting laboratory to perform the above-described bacterial isolation, identification, and immunological or molecular detection assays, point-of-care testing will be helpful [32,33].

Immunochromatographic assays (ICA) have been employed for rapid on-site detection. The colloidal gold-based ICA can meet the urgent need for on-site detection in remote centers; however, it must be conducted by well-trained professionals to ensure the accuracy of the results. An up-converting phosphor technology-based ICA has been developed with advantages of reliability, quantification, and robustness. Portable real-time quantitative PCR may also be applied to detect plague pathogen in the field [34,35].

Diseases:

The arrays of diseases implicated to *Yersinia* spp. can be summarized below:

1-Plague:

Three major forms of plague are usually described, including bubonic, pneumonic, and septicemic plague. However, *Y. pestis* can be transmitted not only by flea bites (causing bubonic plague) and respiratory droplets (causing pneumonic plague), but also by the consumption of uncooked contaminated meat (causing gastrointestinal plague) and contact with infected pets/domestic animals (causing conjunctivitis, skin plague, or pneumonic plague). In addition, plague pharyngitis, meningitis, and endophthalmitis have been reported, albeit rarely. If bubonic plague is not recognized and treated in time, it can develop into pneumonic plague or systemic plague (septicemic plague) by spreading *Y. pestis* via blood; this plague type has a very high mortality rate. Septicemic plague can also be caused directly by blood infection of the pathogen through a cut [36,37].

2-Children Yersiniosis:

The term “*Y. enterocolitica* and *Y. pseudotuberculosis* infections” or “yersiniosis” is applied for two infectious diseases caused by *Yersinia*. These are pseudotuberculosis and intestinal yersiniosis followed by intoxication, injuries to the gastrointestinal tract and multiple organ disorders in case of miscellaneous and

Clinically Important Yersinia: Minireview

multi-disorder disease types. According to course duration of the disease it is classified as an acute (lasts for one month), a protracted (no longer than 3 months) and a chronic form (longer than six months). Concern the virulence traits many studies stated that, YPM genes (the superantigen Y. pseudotuberculosis-derived mitogen) and responsible for the typical pseudotuberculosis symptoms (rash, skin desquamation, red tongue) [38].

3- Far- East Scarlett- Like Fever:

Far East Scarlett-like Fever (FESLF), is manifested via fever, rash and injury of liver and joints and mainly caused by Yersinia pseudotuberculosis. The mainly implicated virulence factor is superantigen Y pseudotuberculosis-derived mitogen A (YPMa) [39,40].

4- Kawasaki Disease

Kawasaki disease (KD), a febrile vasculitis of unknown origin, can cause coronary artery dilation and is increasing in incidence worldwide. The etiology of Kawasaki disease (KD) is unknown. Reportedly, there is an association between KD and Yersinia pseudotuberculosis. It is an enteric pathogen, causes a variety of clinical symptoms such as fever, rash, desquamation, strawberry tongue, lymphadenopathy, and conjunctivitis that sometimes satisfy the clinical criteria for KD. Some research groups have reported an association between YPT and KD [41-44].

Virulence Factors:

1- Y. pseudotuberculosis-derived Mitogen (YPM):

Concern the virulence traits many studies stated that, YPM genes (the superantigen Y. pseudotuberculosis-derived mitogen) and responsible for the typical pseudotuberculosis symptoms (rash, skin desquamation, red tongue). Bacterial superantigens (SAGs) are immunostimulatory toxins that induce acute diseases mainly through the massive release of inflammatory cytokines. Yersinia pseudotuberculosis is the only Gram-negative bacterium known to produce a SAg (Y. pseudotuberculosis-derived mitogen [YPM]). This SAg binds major histocompatibility complex class II molecules on antigen-presenting cells and T cell receptors (TcR) and can activate a potentially hepatotoxic CD4+ T cell population [45]. The

YPM is the only superantigenic toxin identified in Gram-negative bacteria. Superantigens are also produced

by Staphylococcus aureus, Staphylococcus pyrogenes, and some retroviruses. Three YPM variants have been detected: YPMa, YPMb, and YPMc, encoded by chromosomal genes of the same name (ypmA, ypmB, and ypmC). The term "superantigen" refers to YPMa possessing 3 additional properties, in addition to those of a conventional antigen: (1) YPMa is able to bind directly to major histocompatibility complex (MHC) class II molecules on antigen presenting cells; (2) YPMa has a specificity for a set of V β elements, the variable region on the beta chain of a T-cell receptor, and this interaction is independent of antigen specificity; and (3) YPMa is able to activate T cells, which are CD4+ or CD8+, including T cells from donors with different MHC class II allotypes [46].

2- Y. pseudotuberculosis virulence plasmid (pYV)

The presence of the pYV is requisite for pathogenicity in Yersinia species; therefore, the presence or absence of this plasmid divides strains into pathogenic (G1-G3, G5-G6) and nonpathogenic subgroups (G4). Subgroups G2 and G3 comprise the majority of clinical isolates, and subgroups G1, G2, and G6 comprise the minority. The major virulence factors encoded by pYV are a type III secretion system and effector proteins termed Yersinia outer proteins (Yops). The YopE is a GTPase-activating protein, and YopH is a protein tyrosine phosphatase, both of which are antiphagocytic. The YopO/YpkA is a serine threonine kinase. The YopM can transit to the host cell nucleus. The YopJ/P inhibits the production of proinflammatory cytokine tumor necrosis factor- α (TNF- α) and induces macrophage apoptosis. The YopT is a cytotoxin that causes actin filament disruption. All Yops have additionally been shown to disrupt intracellular signaling or result in cytoskeletal changes that interfere with phagocytosis [47,48]. The pYV also encodes proteins involved in the control and translocation of the effector Yops to the target cell: YopN, YopB, YopD, TyeA, lcrG, and lcrV. Pathogenic Yersinia species preferentially target the cells of the innate immune system (neutrophils, macrophages, and dendritic cells) for injection of Yops, attenuating the innate

Clinically Important Yersinia: Minireview

immune response [49]. YadA is an adhesin encoded by plasmid gene carried on pYV. YadA binds collagen I, II, IV, and laminin, and the interactions between YadA and collagen may contribute to chronic *Y. enterocolitica* infections, such as reactive arthritis. YadA supports the creation of densely packed microcolonies of *Yersinia* in three-dimensional collagen gels [50]. YadA also elicits an inflammatory response in epithelial cells by inducing the production of interleukin-8 (IL-8), which is mediated by mitogen-activated protein kinase (MAPK), and by contributing to the intestinal inflammatory cascade. Additionally, YadA mediates cell adhesion and host cell responses induction, like cytokine production, autoagglutination, and serum resistance. YadA also plays a central role in promoting serum resistance. showed that YadA acted as C4-binding protein (C4bp) receptors, and binding of C4bp could help *Y. enterocolitica* to evade complement-mediated clearance in the human host [51,52].

3- High Pathogenicity Island (HPI)

The HPI is a 36-kb chromosomal DNA fragment that carries the biosynthetic gene cluster for yersiniabactin, a molecule involved in siderophore-mediated iron acquisition. Iron uptake is a prerequisite for successful bacterial growth and dissemination. The presence of HPI and yersiniabactin production has been shown to increase virulence [53]. The high-pathogenicity island (HPI) is closely associated with symptoms of *Y. pseudotuberculosis* yersiniosis. The HPI encodes proteins that are involved in the biosynthesis, regulation, and transport of the siderophore yersiniabactin. For that reason, the HPI has been referred to as an “iron capture island.” There are five genes within the island (psn, irp1, irp2, ybtP, and ybtQ) that are involved in the yersiniabactin system. Psn is the outer membrane receptor for the siderophore. The genes irp1 and irp2 encode high-molecular-weight proteins involved in the nonribosomal synthesis of yersiniabactin. irp2 is a marker of high pathogenicity and is found only in pathogenic strains [54,55].

4- Yersinia Chromosomal Virulence Factors (YCVF):

The chromosomal virulence genes include (i) *invA*, encoding a protein that targets host cell surface receptors, which promotes phagocytosis of

the bacteria into the cell, (ii) *ail*, encoding a protein that mediates adhesion and invasion into host cells, and (iii) *ystA* or *ystB*, encoding enterotoxins that cause fluid accumulation in the intestines. Virulent strains carry virulence genes *ystA*, *invA* and *ail*, whilst less virulent strains carry *ystB* [56,57]. Some studies showed that in an early phase of *Y. enterocolitica* infection, *InvA* is required for effective bacteria translocation into M cells and Peyer’s patches colonization. *InvA* binds to integrins, which leads to the creation of integrin clusters, triggers remodeling of the actin cytoskeleton and leads to the internalization of *Y. enterocolitica* to epithelial cells. The above is known as the “zipper” invasion mechanism, and internalization allows the delivery of Yops to host cells [58,59].

Treatment:

Y. pestis isolates worldwide are sensitive to streptomycin; however, a multidrug-resistant (MDR) strain was isolated from Madagascar. Fortunately, this MDR strain has never emerged again naturally in this region and other parts of the world. There is a concern that this MDR strain (resistant to streptomycin, chloramphenicol, ampicillin, spectinomycin, kanamycin, tetracycline, sulfonamides, and minocycline) may be attractive to bioterrorists who may want to perpetuate a bioterrorism attack using this strain. If infection by such a strain does occur, caution must be used in the selection of effective antibiotics by avoiding administration of the above-mentioned ones. The majority of human cases can be treated successfully with effective antibiotics according to the United States Centers for Disease Control and Prevention (CDC)’s recommendation. Streptomycin and gentamicin are recommended for adult patients, including immunocompromised patients and pregnant women. Streptomycin and gentamicin may also be administered in children; however, the dosage should be reduced. Alternatively, the combination of doxycycline, ciprofloxacin, and chloramphenicol could also be used for both adults and children [60,61].

Antimicrobial therapy is not usually recommended for treating enterocolitis in immunocompetent hosts since most of the gastrointestinal infections are self-limiting. However, immunocompromised patients with invasive infection, who are at increased risk for

Clinically Important *Yersinia*: Minireview

developing bacteremia or even septicemia, need special attention and antibiotic treatment since the mortality rate in these cases can be as high as 50% [62]. According to the common profile of susceptibility among *Y. enterocolitica* strains the initial recommendations for antimicrobial chemotherapy from public institutions, such as the WHO, included tetracycline, chloramphenicol, gentamicin, and cotrimoxazole. However, other compounds such as ciprofloxacin, ceftriaxone, and cefotaxime are also considered since they have shown excellent in vitro activity and have been successfully used to treat complicated infections (liver abscess, endocarditis, and septicemia) [63,64].

Antibiotic Resistance and Serotypes

The resistance profiles to different antimicrobial agents have been examined among strains collected from animal and environmental reservoirs, meat products, as well as those recovered from the clinical setting. Heterogeneity of the antimicrobial resistance pattern is shown to be depending on the bioserotype and geographical distribution. The levels of resistance to β -lactams, which are the major family of antibiotics currently used, have been extensively studied in strains of both animal and human origin. In general terms, high percentages of resistance to ampicillin are detected: values $>85\%$ resistance have been reported for non-clinical strains and $>95\%$ in the case of clinical isolates. Nonetheless, lower rates of resistance have been reported (13–57.1%) for strains obtained from the animal and, to a lesser extent from the human, setting [65-68].

In the case of amoxicillin/clavulanic acid, heterogeneous susceptibility profiles have been seen among *Y. enterocolitica* strains. High levels of resistance (100% for non-clinical strains and $>75\%$ for clinical isolates) have been shown to occur in strains belonging to biotypes 1A, 2, and 3 collected from around the world, including serotype O:5,27 strains from Canada (presumably related to biotypes 2 or 3 according to the most prevalent biotype-serotype associations). However, reported very low levels of resistance ($<3\%$) for strains serotyped as O:5 and O:9 (putatively belonging to biotypes 2 or 3) obtained from animals in the United States. On the other hand, bioserotype 4/O:3 consistently shows the lowest resistance values, $<10\%$, among all the isolates regardless of the country of isolation.

Similar to the resistance levels observed for ampicillin, most of the *Y. enterocolitica* strains are also resistant to cefalothin, a first-generation cephalosporin. Several studies have reported percentages of resistance $>85\%$ in strains of animal origin and $>98\%$ in strains isolated from humans [69].

Fortunately, most of the strains studied remain susceptible to more recent cephalosporins, including the second-generation compound cefuroxime and third-generation cephalosporins such as ceftriaxone, ceftazidime, and cefotaxime. Similarly, a more recent study conducted in Switzerland showed that all bioserotype 4/O:3 clinical isolates were susceptible, while higher resistance rates were observed for biotype 1A (45%) and bioserotypes 2/O:5,27, 2/O:9, and 3/O:3 ($>80\%$) [70]. Information regarding imipenem resistance is also scarce. To our knowledge, only one study from Greece has been conducted, showing 8% of the strains of animal origin to be resistant to this drug. With respect to clinical isolates, no resistance to imipenem has been reported. Other antimicrobials which deserve to be highlighted are those belonging to the group of aminoglycosides. Full susceptibility to kanamycin and gentamicin has been reported in almost all studies regardless of the source of isolation [71]. Higher heterogeneity has been observed for streptomycin among clinical and non-clinical strains. Several studies have revealed a lack of resistance, particularly concerning biotype 2 strains, while others have reported levels of resistance ranging from 5.6% to 28.6%. The highest levels of resistance to streptomycin have been described for strains belonging to bioserotype 4/O:3. Among strains of animal origin, studies carried out in Italy and Germany showed percentages of resistance of 64% and 75%, respectively. In the clinical setting, strains isolated in Spanish hospitals have reported the highest levels of resistance to streptomycin ($\geq 90\%$); whereas the remaining studies, also performed in Europe, show a prevalence of resistance $<30\%$. Cases in which high levels of resistance have been reported are attributed to horizontal transfer of plasmids carrying genes which confer resistance to streptomycin [72,73].

References

1. Murros-Kontinen A, Johansson P, Niskanen T, Fredriksson-Ahomaa M, Korkeala H, &

Clinically Important *Yersinia*: Minireview

- Björkroth J (2011a) *Yersinia pekkanenii* sp. nov. *Int J Syst Evol Microbiol* 61: 2363- 2367.
- Murros-Konttinen A, Fredriksson-Ahomaa M, Korkeala H, Johansson P, Rahkila R, & Björkroth J (2011b) *Yersinia nurmii* sp. nov. *Int J Syst Evol Microbiol* 61: 2368-2372.
 - Savin, C., Martin, L., Bouchier, C., Filali, S., Chenau, J., Zhou, Z., Becher, F., Fukushima, H., Thomson, N.R., Scholz, H.C. and Carniel, E., 2014. The *Yersinia pseudotuberculosis* complex: characterization and delineation of a new species, *Yersinia wautersii*. *International Journal of Medical Microbiology*, 304(3-4), pp.452-463.
 - von Tils, D., I. Blädel, M. A. Schmidt, and G. Heusipp. 2012. Type II secretion in *Yersinia*—a secretion system for pathogenicity and environmental fitness. *Front. Cell. Infect. Microbiol.* 2:160.
 - McNally, A., Thomson, N.R., Reuter, S. and Wren, B.W., 2016. 'Add, stir and reduce': *Yersinia* spp. as model bacteria for pathogen evolution. *Nature Reviews Microbiology*, 14(3), p.177.
 - Bottone, EJ, Bercovier, H, Mollaret, HH. *Yersinia*. In: Brenner DJ, Krieg NR, Staley JT and Garrity GM (editors). *Bergey's Manual of Systematic Bacteriology*, 2nd ed, Vol. 2. New York, NY: SpringerVerlag; 2005.
 - Fredriksson-Ahomaa, M., Meyer, C., Bonke, R., Stuber, E., Wacheck, S., 2010. Characterization of *Yersinia enterocolitica* 4/O:3 isolates from tonsils of Bavarian slaughter pigs. *Lett. Appl. Microbiol.* 50, 412–418.
 - Reuter, S., Connor, T.R., Barquist, L., Walker, D., Feltwell, T., Harris, S.R., Fookes, M., Hall, M.E., Petty, N.K., Fuchs, T.M. and Corander, J., 2014. Parallel independent evolution of pathogenicity within the genus *Yersinia*. *Proceedings of the National Academy of Sciences*, 111(18), pp.6768-6773.
 - Carniel E, Autenrieth I, Cornelis G, Fukushima H, Guinet F, Isberg R, Pham J, Prentice M, Simonet M, Skurnik M, Wauters G (2006) *Y. enterocolitica* and *Y. pseudotuberculosis*. In *The Prokaryotes, A Handbook on the Biology of Bacteria, Volume 6: Proteobacteria: Gamma Subclass*, Dworkin M, Falkow S, Rosenberg E, Schleifer K-, Stackebrandt E (eds) pp 270-398. Springer: New York.
 - Sprague, L.D., Scholz, H.C., Amann, S., Busse, H.J. and Neubauer, H., 2008. *Yersinia similis* sp. nov. *International journal of systematic and evolutionary microbiology*, 58(4), pp.952-958.
 - Laukkanen-Ninios, R., Didelot, X., Jolley, K.A., Morelli, G., Sangal, V., Kristo, P., Brehony, C., Imori, P.F., Fukushima, H., Siitonen, A. and Tseneva, G., 2011. Population structure of the *Yersinia pseudotuberculosis* complex according to multilocus sequence typing. *Environmental microbiology*, 13(12), pp.3114-3127.
 - Fredriksson-Ahomaa, M., and H. Korkeala. 2003. Low occurrence of pathogenic *Yersinia enterocolitica* in clinical, food, and environmental samples: A methodological problem. *Clin. Microbiol. Rev.* 229–16:220
 - Weagant, S., and P. Feng. 2001. *Yersinia*. Pages 421–428 in *Compendium of Methods for the Microbiological Examination of Foods*, 3th ed. F. Pouch Downes and K. Ito, ed. American Public Health Association, Washington DC.
 - Cui, Y., Yu, C., Yan, Y., Li, D., Li, Y., Jombart, T., Weinert, L.A., Wang, Z., Guo, Z., Xu, L. and Zhang, Y., 2013. Historical variations in mutation rate in an epidemic pathogen, *Yersinia pestis*. *Proceedings of the National Academy of Sciences*, 110(2), pp.577-582.
 - Wagner, D.M., Klunk, J., Harbeck, M., Devault, A., Waglechner, N., Sahl, J.W., Enk, J., Birdsell, D.N., Kuch, M., Lumibao, C. and Poinar, D., 2014. *Yersinia pestis* and the Plague of Justinian 541–543 AD: a genomic analysis. *The Lancet infectious diseases*, 14(4), pp.319-326.
 - Yang, R., 2018. Plague: recognition, treatment, and prevention. *Journal of clinical microbiology*, 56(1), pp.e01519-17.
 - Duan, R., Liang, J., Shi, G., Cui, Z., Hai, R., Wang, P., Xiao, Y., Li, K., Qiu, H., Gu, W. and Du, X., 2014. Homology analysis of pathogenic *Yersinia* species *Yersinia enterocolitica*, *Yersinia pseudotuberculosis*, and *Yersinia pestis* based on multilocus sequence typing. *Journal of clinical microbiology*, 52(1), pp.20-29.

Clinically Important *Yersinia*: Minireview

18. De Castro, C., Kenyon, J.J., Cunneen, M.M., Molinaro, A., Holst, O., Skurnik, M. and Reeves, P.R., 2012. The O-specific polysaccharide structure and gene cluster of serotype O: 12 of the *Yersinia pseudotuberculosis* complex, and the identification of a novel L-quinovose biosynthesis gene. *Glycobiology*, 23(3), pp.346-353.
19. Pärn T, Hallanvuo S, Salmenlinna S, Pihlajasaari A, Heikkinen S et al. Outbreak of *Yersinia pseudotuberculosis* O:1 infection associated with raw milk consumption, Finland, Spring 2014. *Euro Surveill* 2015;20.
20. Timchenko, N.F., Adgamov, R.R., Popov, A.F., Psareva, E.K., Sobyenin, K.A., Gintsburg, A.L. and Ermolaeva, S.A., 2016. Far East Scarlet-like fever caused by a few related genotypes of *Yersinia pseudotuberculosis*, Russia. *Emerging infectious diseases*, 22(3), p.503.
21. Ho, N., Kondakova, A.N., Knirel, Y.A. and Creuzenet, C., 2008. The biosynthesis and biological role of 6-deoxyheptose in the lipopolysaccharide O-antigen of *Yersinia pseudotuberculosis*. *Molecular microbiology*, 68(2), pp.424-447.
22. Erickson, D.L., Lew, C.S., Kartchner, B., Porter, N.T., McDaniel, S.W., Jones, N.M., Mason, S., Wu, E. and Wilson, E., 2016. Lipopolysaccharide biosynthesis genes of *Yersinia pseudotuberculosis* promote resistance to antimicrobial chemokines. *PLoS one*, 11(6), p.e0157092.
23. Thoerner, P., C. B. Kingombe, K. Bögli-Stuber, B. Bissig-Choisat, T. Wassenaar, J. Frey, and T. Jemmi. 2003. PCR detection of virulence genes in *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* and investigation of virulence gene distribution. *Appl. Environ. Microbiol.* 69:1810–1816
24. Fredriksson-Ahomaa, M., A. Stolle, and H. Korkeala. 2006. Molecular epidemiology of *Yersinia enterocolitica* infections. *FEMS Immunol. Med. Microbiol.* 47:315–329.
25. Wong D, Wild MA, Walburger MA, Higgins CL, Callahan M, Czarnecki LA, Lawaczek EW, Levy CE, Patterson JG, Sunenshine R, Adem P, Paddock CD, Zaki SR, Petersen JM, Schriefer ME, Eisen RJ, Gage KL, Griffith KS, Weber IB, Spraker TR, Mead PS. 2009. Primary pneumonic plague contracted from a mountain lion carcass. *Clin Infect Dis* 49:e33–38.
26. Wang H, Cui Y, Wang Z, Wang X, Guo Z, Yan Y, Li C, Cui B, Xiao X, Yang Y, Qi Z, Wang G, Wei B, Yu S, He D, Chen H, Chen G, Song Y, Yang R. 2011. A dog-associated primary pneumonic plague in Qinghai Province, China. *Clin Infect Dis* 52:185–190.
27. European Food Safety Authority. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2015. *EFSA Journal* 2016;14:e04634.
28. Banczerz-Kisiel A, Szweda W. Yersiniosis – zoonotic foodborne disease of relevance to public health. *Ann Agric Environ Med* 2015;22:397–402.
29. MacDonald E, Einöder-Moreno M, Borgen K, Thorstensen Brandal L, Diab L et al. National outbreak of *Yersinia enterocolitica* infections in military and civilian populations associated with consumption of mixed salad, Norway, 2014. *Euro Surveill* 2016;21.
30. Williamson DA, Baines SL, Carter GP, da Silva AG, Ren X et al. Genomic insights into a sustained national outbreak of *Yersinia pseudotuberculosis*. *Genome Biol Evol* 2016;8:3806–3814.
31. Prentice MB, Rahalison L. 2007. Plague. *Lancet* 369:1196–1207.
32. Qi Z, Wu Y, Li Y, Li C, Yang X, Zhang Q, Xin Y, Jin Y, Wei R, Cui Y. 2015. 3a-Negative *Yersinia pestis*, China. *Infect Dis Transl Med* 1:61–62. <https://doi.org/10.11979/idthm.201502004>.
33. Qu S, Shi QH, Zhou L, Guo ZB, Zhou DS, Zhai JH, Yang RF. 2010. Ambient stable quantitative PCR reagents for the detection of *Yersinia pestis*. *PLoS Negl Trop Dis* 4:e629.
34. Mölsä M, Hemmila H, Katz A, Niemimaa J, Forbes KM, Huitu O, Stuart P, Henttonen H, Nikkari S. 2015. Monitoring biothreat agents (*Francisella tularensis*, *Bacillus anthracis* and *Yersinia pestis*) with a portable real-time PCR instrument. *J Microbiol Methods* 115:89–93.
35. Zhang PP, Hua F, Yu XT, Qu F, Xie H, Zhao Y, Zhao XL, Jin LX, Yu AL, Cui BZ, Zhou L. 2015. Rapid detection of *Yersinia pestis* antigen from decomposed rodent viscera using

Clinically Important Yersinia: Minireview

- an up-converting phosphor technologybased lateral-flow assay. *Infect Dis Transl Med* 1:57.
36. Anisimov AP, Amoako KK. 2006. Treatment of plague: promising alternatives to antibiotics. *J Med Microbiol* 55:1461–1475.
 37. Walloe L. 2008. Medieval and modern bubonic plague: some clinical continuities. *Med Hist Suppl* 2008(27):59–73.
 38. Kokorina, G.I. and Shestakova, M.D., 2018. Possibilities of non-invasive methods application for diagnosis of yersiniosis in children. *Инфекция и иммунитет*, 8(4), pp.635-635.
 39. Ermolaeva, S.A., Timchenko, N.F., Psareva, E.A. and Adgamov, R.R., 2018. Genetic determinants characteristic for *Yersinia pseudotuberculosis* strains isolated from patients with Far-East Scarlet-Like Fever. *Инфекция и иммунитет*, 8(4), pp.633-633.
 40. Amphlett, A., 2016, January. Far East scarlet-like fever: a review of the epidemiology, symptomatology, and role of superantigenic toxin: *Yersinia pseudotuberculosis*-derived mitogen A. In *Open forum infectious diseases* (Vol. 3, No. 1). Oxford University Press.
 41. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. *J Epidemiol*. 2012;22:79–85.
 42. Huang SK, Lin MT, Chen HC, Huang SC, Wu MH. Epidemiology of Kawasaki disease: prevalence from national database and future trends projection by system dynamics modeling. *J Pediatr*. 2013;163:126–31. e121.
 43. Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, Jape G, et al. The epidemiology and clinical features of Kawasaki disease in Australia. *Pediatrics*. 2014;133:e1009–14.
 44. Horinouchi, T., Nozu, K., Hamahira, K., Inaguma, Y., Abe, J., Nakajima, H., Kugo, M. and Iijima, K., 2015. *Yersinia pseudotuberculosis* infection in Kawasaki disease and its clinical characteristics. *BMC pediatrics*, 15(1), p.177.
 45. Goubard, A., Loiez, C., Abe, J., Fichel, C., Herwegh, S., Faveeuw, C., Porte, R., Cayet, D., Sebbane, F., Penet, S. and Foligné, B., 2015. Superantigenic *Yersinia pseudotuberculosis* induces the expression of granzymes and perforin by CD4+ T cells. *Infection and immunity*, 83(5), pp.2053-2064.
 46. Zippelius A, Pittet MJ, Batard P et al. . Thymic selection generates a large T cell pool recognizing a self-peptide in humans. *J Exp Med* 2002; 195:485–94.
 47. Fukushima H, Matsuda Y, Seki R. Geographical heterogeneity between Far East and Western countries in prevalence of the virulence plasmid, the superantigen *Yersinia pseudotuberculosis* derived mitogen and the high-pathogenicity island among *Yersinia pseudotuberculosis* strains. *J Clin Microbiol* 2001; 39:3541–7.
 48. Dube P. Interaction of *Yersinia* with the gut: mechanisms of pathogenesis and immune evasion. *Curr Top Microbiol Immunol* 2009; 337:61–91.
 49. Marketon MM, DePaolo RW, DeBord KL et al. . Plague bacteria target immune cells during infection. *Science* 2005; 309:1739–41.
 50. Uliczka, F., Pisano, F., Schaake, J., Stolz, T., Rohde, M., Fruth, A., Strauch, E., Skurnik, M., Batzilla, J., Rakin, A. and Heesemann, J., 2011. Unique cell adhesion and invasion properties of *Yersinia enterocolitica* O: 3, the most frequent cause of human Yersiniosis. *PLoS pathogens*, 7(7), p.e1002117.
 51. Kirjavainen, V., Jarva, H., Biedzka-Sarek, M., Blom, A.M., Skurnik, M. and Meri, S., 2008. *Yersinia enterocolitica* serum resistance proteins YadA and Ail bind the complement regulator C4b-binding protein. *PLoS pathogens*, 4(8), p.e1000140.
 52. Mühlkamp, M., Oberhettinger, P., Leo, J.C., Linke, D. and Schuetz, M.S., 2015. *Yersinia* adhesin A (YadA)—beauty & beast. *International Journal of Medical Microbiology*, 305(2), pp.252-258.
 53. Carniel E. The *Yersinia* high-pathogenicity island: an iron-uptake island. *Microbes Infect* 2001; 3:561–9.
 54. Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, Curtiss R, III. 2010. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated *Salmonella* as a vaccine against bubonic and pneumonic *Yersinia pestis* challenge. *Vaccine* 29:274–282.

Clinically Important *Yersinia*: Minireview

55. Garzetti D, Susen R, Fruth A, Tietze E, Heesemann J et al. A molecular scheme for *Yersinia enterocolitica* patho-serotyping derived from genome-wide analysis. *Int J Med Microbiol* 2014;304:275–283.
56. Atkinson S, Williams P. *Yersinia* virulence factors - a sophisticated arsenal for combating host defences. *F1000Res* 2016;5:1370.
57. Schmid, Y.; Grassl, G.A.; Bühler, O.T.; Skurnik, M.; Autenrieth, I.B.; Bohn, E. *Yersinia enterocolitica* Adhesin A induces production of interleukin-8 in epithelial cells. *Infect. Immun.* 2004, 72, 6780–6789.
58. Mikula, K.M.; Kolodziejczyk, R.; Goldman, A. *Yersinia* infection tools—Characterization of structure and function of adhesins. *Front. Cell. Infect. Microbiol.* 2013, 8, 169.
59. Nikiforov, V.V., Gao, H., Zhou, L. and Anisimov, A., 2016. Plague: clinics, diagnosis and treatment. In *Yersinia pestis: Retrospective and Perspective* (pp. 293-312). Springer, Dordrecht.
60. Apangu, T., Griffith, K., Abaru, J., Candini, G., Apio, H., Okoth, F., Okello, R., Kaggwa, J., Acayo, S., Ezama, G. and Yockey, B., 2017. Successful treatment of human plague with oral ciprofloxacin. *Emerging infectious diseases*, 23(3), p.553.
61. Fabrega, A., Vila, J., 2012. *Yersinia enterocolitica*: pathogenesis, virulence and antimicrobial resistance. *Enferm. Infecc. Microbiol. Clin.* 30, 24–32.
62. Chiu, S., Huang, Y.C., Su, L.H., Lin, T.Y., 2003. *Yersinia enterocolitica* sepsis in an adolescent with Cooley's anemia. *J. Formos. Med. Assoc.* 102, 202–204.
63. Abdel-Haq, N.M., Papadopol, R., Asmar, B.I., Brown, W.J., 2006. Antibiotic susceptibilities of *Yersinia enterocolitica* recovered from children over a 12-year period. *Int. J. Antimicrob. Agents* 27, 449–452.
64. Bonke, R., Wacheck, S., Stuber, E., Meyer, C., Martlbauer, E., Fredriksson-Ahomaa, M., 2011. Antimicrobial susceptibility and distribution of beta-lactamase A (*blaA*) and beta-lactamase B (*blaB*) genes in enteropathogenic *Yersinia* species. *Microb. Drug Resist.* 17, 575–581.
65. Novoslavskij, A., Kudirkiene, E., Marcinkute, A., Bajoriuniene, A., Korkeala, H., Malakauskas, M., 2013. Genetic diversity and antimicrobial resistance of *Yersinia enterocolitica* isolated from pigs and humans in Lithuania. *J. Sci. Food Agric.* 93, 1858–1862.
66. Tadesse, D.A., Bahnson, P.B., Funk, J.A., Morrow, W.E., Abley, M.J., Ponte, V.A., et al., 2013. *Yersinia enterocolitica* of porcine origin: carriage of virulence genes and genotypic diversity. *Foodborne Pathog. Dis.* 10, 80–86.
67. Bonardi, S., Alpighiani, I., Pongolini, S., Morganti, M., Tagliabue, S., Bacci, C., et al., 2014. Detection, enumeration and characterization of *Yersinia enterocolitica* 4/O:3 in pig tonsils at slaughter in Northern Italy. *Int. J. Food Microbiol.* 177, 9–15.
68. Fredriksson-Ahomaa, M., Cernela, N., Hachler, H., Stephan, R., 2012. *Yersinia enterocolitica* strains associated with human infections in Switzerland 2001–2010. *Eur. J. Clin. Microbiol. Infect. Dis.* 31, 1543–1550.
69. Gousia, P., Economou, V., Sakkas, H., Leveidiotou, S., Papadopoulou, C., 2011. Antimicrobial resistance of major foodborne pathogens from major meat products. *Foodborne Pathog. Dis.* 8, 27–38.
70. Terentjeva, M., Berzins, A., 2010. Prevalence and antimicrobial resistance of *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* in slaughter pigs in Latvia. *J. Food Prot.* 73, 1335–1338.
71. Mayrhofer, S., Paulsen, P., Smulders, F.J., Hilbert, F., 2004. Antimicrobial resistance profile of five major food-borne pathogens isolated from beef, pork and poultry. *Int. J. Food Microbiol.* 97, 23–29.
72. Baumgartner, A., Kuffer, M., Suter, D., Jemmi, T., Rohner, P., 2007. Antimicrobial resistance of *Yersinia enterocolitica* strains from human patients, pigs and retail pork in Switzerland. *Int. J. Food Microbiol.* 115, 110–114.
73. Bhaduri, S., Wesley, I., Richards, H., Draughon, A., Wallace, M., 2009. Clonality and antibiotic susceptibility of *Yersinia enterocolitica* isolated from U.S. market weight hogs. *Foodborne Pathog. Dis.* 6, 351–356.

Clinically Important Yersinia: Minireview

How to Cite: Dheyab, Z. S. . (2022). Clinically Important Yersinia: Minireview . Journal of Medical Research and Health Sciences, 5(10), 2295–2306. <https://doi.org/10.52845/JMRHS/2022-5-10-3>